Enzymotec Ltd (NASDAQ:ENZY)‘s stock had its “buy” rating reiterated by research analysts at Canaccord Genuity in a research report issued to clients and investors on Thursday, MarketBeat.com reports. They currently have a $10.00 price objective on the stock. Canaccord Genuity’s price target indicates a potential upside of 24.69% from the company’s previous close. An institutional […]
